| Literature DB >> 26823510 |
Abstract
In this issue of Blood, Hong et al advocate for use of additional US Food and Drug Administration (FDA)–approved safety measures for transfusion. Most patients transfused with contaminated platelets do not show immediate clinical signs. Active surveillance suggests patient risk 10- to 40-fold higher than passive hemovigilance.Entities:
Mesh:
Year: 2016 PMID: 26823510 DOI: 10.1182/blood-2015-12-685198
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113